Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia: an 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.

Trial Profile

Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia: an 8-Week, Randomized, Double-Blind, Placebo-Controlled Trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Feb 2014

At a glance

  • Drugs Pregnenolone (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Feb 2014 Results published in the Psychiatry and Clinical Neurosciences.
    • 27 Jun 2013 Primary endpoint 'Schedule-for-Assessment-of-Negative-Symptoms' has been met according to results presented at the 11th World Congress of Biological Psychiatry.
    • 27 Jun 2013 Results presented at the 11th World Congress of Biological Psychiatry.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top